CELSET Launches SOLTOX in International Markets

SEOUL, South Korea, Oct. 28, 2026 /CourierPR/ -- CELSET Inc., a Korean biotechnology company specializing in medical aesthetics, has launched SOLTOX, its botulinum toxin type A brand, into international markets. This move marks a significant step for the company, as it aims to establish a presence in the global medical aesthetics sector.

SOLTOX is available in two formulations: 100 Unit and 200 Unit. The product is characterized by three key technical attributes: a 900 kDa toxin complex, a freeze-dried dosage form, and an advanced purification process. These features reflect CELSET's commitment to controlled manufacturing processes, product characterization, and pharmaceutical quality.

The 900 kDa toxin complex refers to the molecular size of the botulinum toxin protein complex, including associated proteins. This characteristic identifies a specific formulation feature rather than establishing any claim of superior clinical duration or efficacy. SOLTOX is supplied as a lyophilized powder, intended for reconstitution before administration by qualified medical professionals, in accordance with applicable product labeling and local requirements.

Purification is another central element of the SOLTOX manufacturing approach. Advanced Botulinum Toxin Purification Technology is applied during the processing of botulinum toxin type A, with emphasis on separating the desired substance from unwanted materials. The production process also involves controlled manufacturing conditions and botulinum toxin quality control procedures covering preparation, filling, freeze drying, and batch assessment.

CELSET highlights these manufacturing characteristics as the technical foundation of SOLTOX. The brand's positioning focuses on formulation identity and process controls, without equating manufacturing characteristics with unverified differences in patient outcomes. The company emphasizes a consistent brand presentation and clear information for healthcare professionals across different markets.

The launch of SOLTOX establishes CELSET within the international medical aesthetics activities. The brand's positioning reflects the growing visibility of Korean biotechnology and medical aesthetics manufacturing, alongside the importance of established medical channels and market-specific regulatory frameworks. CELSET views country-level market development and professional relationships as integral to the international presence of the SOLTOX brand.

SOLTOX's introduction broadens CELSET's medical aesthetics portfolio, complementing its focus on scientifically grounded product communication. The company emphasizes a consistent brand presentation and clear information for healthcare professionals across different markets. Availability and use are governed by the regulatory requirements applicable in each country.

In summary, CELSET Inc. has launched SOLTOX, a botulinum toxin type A brand, into international markets. The product is characterized by a 900 kDa toxin complex, a freeze-dried dosage form, and an advanced purification process, reflecting the company's commitment to controlled manufacturing and pharmaceutical quality.